Potassium Chloride And Dextrose Monohydrate
Generic Name: potassium chloride and dextrose monohydrate
Brand Names:
Potassium Chloride In Dextrose
11 DESCRIPTION Potassium Chloride in Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single-dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1. Table 1 Size (mL) Composition (g/L) Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
Overview
11 DESCRIPTION Potassium Chloride in Dextrose Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single-dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1. Table 1 Size (mL) Composition (g/L) Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
Uses
1 INDICATIONS AND USAGE Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories. Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories. (1)
Dosage
2 DOSAGE AND ADMINISTRATION • Only for intravenous infusion. (2.1 , 5.2) • See full prescribing information for information on preparation, administration, dosing considerations and instructions for use. (2.1 , 2.2, 2.3) 2.1 Important Administration Instructions • Potassium Chloride in Dextrose Injection is only for intravenous infusion [see Warnings and Precautions (5.2) ] . • For patients receiving Potassium Chloride in Dextrose Injection at greater than maintenance rates, frequent monitoring of serum potassium concentrations and serial electrocardiograms (ECGs) are recommended. • The osmolarity of Potassium Chloride in Dextrose Injection is 293 mOsmol/L (calc).
Side Effects
6 ADVERSE REACTIONS The following adverse reactions associated with the use of Potassium Chloride in Dextrose Injection were identified in post marketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions : including anaphylaxis and chills [see Warnings and Precautions (5.1) ] .
Interactions
7 DRUG INTERACTIONS • Other Products that Cause Hyperkalemia : Avoid use in patients receiving such products. If use cannot be avoided, monitor serum potassium concentrations. (7.1) • Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance : Monitor blood glucose concentrations, fluid balance serum electrolyte concentrations and acid-base balance.
Warnings
5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions : monitor for signs and symptoms and discontinue infusion if reactions occur. (5.1) • Hyperkalemia : May result in cardiac arrhythmias. Avoid use in patients with, or at risk for, hyperkalemia. If use cannot be avoided, use a product with a low amount of potassium chloride, infuse slowly and monitor serum potassium concentrations and ECGs. (5.2) • Hyperglycemia or Hyperosmolar Hyperglycemic State : Monitor blood glucose and administer insulin as needed. (5.3 , 8.4) • Hyponatremia : Avoid in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations. (5.4 , 8.4) • Hypokalemia: Avoid in patients with or at risk for hypokalemia. If use cannot be avoided, monitor serum potassium levels. 4 CONTRAINDICATIONS Potassium Chloride in Dextrose Injection is contraindicated in patients with: • known hypersensitivity to potassium chloride and/or dextrose [see Warnings and Precautions 5.1) ] • clinically significant hyperkalemia [see Warnings and Precautions (5.2) ] • clinically significant hyperglycemia [see Warnings and Precautions (5.3) ] • Known hypersensitivity to potassium chloride or...
Pregnancy
8.1 Pregnancy Risk Summary Appropriate administration of Potassium Chloride in Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. Animal reproduction studies have not been conducted with Potassium Chloride in Dextrose Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING Potassium Chloride in 5% Dextrose Injection, is a clear solution in 1000 mL single-dose, flexible containers available as follows: Code Size (mL) NDC Product Name 2B1134 1000 0338-0683-04 20 mEq Potassium Chloride in 5% Dextrose Injection, USP Storage: Avoid excessive heat.
Frequently Asked Questions
What is Potassium Chloride And Dextrose Monohydrate used for?▼
1 INDICATIONS AND USAGE Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories. Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories. (1)
What are the side effects of Potassium Chloride And Dextrose Monohydrate?▼
6 ADVERSE REACTIONS The following adverse reactions associated with the use of Potassium Chloride in Dextrose Injection were identified in post marketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions : including anaphylaxis and chills [see Warnings and Precautions (5.1) ] .
Can I take Potassium Chloride And Dextrose Monohydrate during pregnancy?▼
8.1 Pregnancy Risk Summary Appropriate administration of Potassium Chloride in Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. Animal reproduction studies have not been conducted with Potassium Chloride in Dextrose Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.
What are the important warnings for Potassium Chloride And Dextrose Monohydrate?▼
5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions : monitor for signs and symptoms and discontinue infusion if reactions occur. (5.1) • Hyperkalemia : May result in cardiac arrhythmias. Avoid use in patients with, or at risk for, hyperkalemia. If use cannot be avoided, use a product with a low amount of potassium chloride, infuse slowly and monitor serum potassium concentrations and ECGs. (5.2) • Hyperglycemia or Hyperosmolar Hyperglycemic State : Monitor blood glucose and administer insulin as needed. (5.3 , 8.4) • Hyponatremia : Avoid in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations. (5.4 , 8.4) • Hypokalemia: Avoid in patients with or at risk for hypokalemia. If use cannot be avoided, monitor serum potassium levels. 4 CONTRAINDICATIONS Potassium Chloride in Dextrose Injection is contraindicated in patients with: • known hypersensitivity to potassium chloride and/or dextrose [see Warnings and Precautions 5.1) ] • clinically significant hyperkalemia [see Warnings and Precautions (5.2) ] • clinically significant hyperglycemia [see Warnings and Precautions (5.3) ] • Known hypersensitivity to potassium chloride or...
Related Medications
Tamsulosin Hydrochloride
tamsulosin hydrochloride
11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. Tamsulosin hydrochloride is (-)-( R )-5-[2-[[2-( o -Ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride. Tamsulosin hydrochloride USP is a white or almost white crystalline powder that melts with decomposition at approximately 230°C. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether.
Buprenorphine Sublingual C-iii
buprenorphine sublingual c-iii
Buprenorphine Sublingual Tablets are supplied as white, sublingual tablets available in two dosage strengths, 2 mg buprenorphine free base and 8 mg buprenorphine free base. Each tablet also contains citric acid anhydrous, corn starch, crospovidone, lactose monohydrate, magnesium stearate, mannitol, povidone, purified water and sodium citrate.
Medulla Ossis Suis, Spleen (bovine), Thymus (bovine), Carcinosin, Cytomegalovirus Nosode, Influenzinum (2022-2023), Streptococcus Viridans, Toxoplasma Gondii, Epstein-bar Virus Nosode
medulla ossis suis, spleen (bovine), thymus (bovine), carcinosin, cytomegalovirus nosode, influenzinum (2022-2023), streptococcus viridans, toxoplasma gondii, epstein-bar virus nosode
PURPOSE: Assists in temporary relief of fatigue and headaches.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.